| Star Valley Medical Center | |
|
901 Adams Afton WY 83110-9621 | |
| (307) 885-5800 | |
| (307) 885-5865 |
| Full Name | Star Valley Medical Center |
|---|---|
| Speciality | Family Medicine |
| Location | 901 Adams, Afton, Wyoming |
| Authorized Official Name and Position | Denise Wheeler (REV CYCLE DIRECTOR) |
| Authorized Official Contact | 3078855877 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Star Valley Medical Center 901 Adams Afton WY 83110-9621 Ph: (307) 885-5800 | Star Valley Medical Center 901 Adams Afton WY 83110-9621 Ph: (307) 885-5800 |
| NPI Number | 1730132523 |
|---|---|
| Provider Enumeration Date | 05/19/2006 |
| Last Update Date | 12/02/2014 |
| Medicare PECOS PAC ID | 4789580218 |
|---|---|
| Medicare Enrollment ID | O20031208000415 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730132523 | NPI | - | NPPES |
| 114481204 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (Wyoming) | Primary |
| 275N00000X | Medicare Defined Swing Bed Unit | 10309 (Wyoming) | Secondary |
| 341600000X | Ambulance | 09184 (Wyoming) | Secondary |
| Provider Name | Donald J Kirk |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861447971 PECOS PAC ID: 2567451164 Enrollment ID: I20040510000331 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Ryan T Clifford |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295773505 PECOS PAC ID: 7113810557 Enrollment ID: I20040614001462 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Edward J Frink |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1154402451 PECOS PAC ID: 7810960416 Enrollment ID: I20040817000784 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Tamara O Cottam |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164488185 PECOS PAC ID: 2062481732 Enrollment ID: I20040930000324 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Curt R Stock |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1275681686 PECOS PAC ID: 5496653990 Enrollment ID: I20050513000226 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jim D Wheeler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255351763 PECOS PAC ID: 4486677457 Enrollment ID: I20060112000118 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Edward A Henry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437104536 PECOS PAC ID: 3274545538 Enrollment ID: I20060705000072 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Joshua D Beck |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1295789089 PECOS PAC ID: 7810907003 Enrollment ID: I20061128000325 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | David M Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851314785 PECOS PAC ID: 1254330558 Enrollment ID: I20061214000448 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Shannan Raquel Wright |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1427004910 PECOS PAC ID: 7719977602 Enrollment ID: I20071119000371 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Martha S Hageman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033395561 PECOS PAC ID: 9537242466 Enrollment ID: I20080214000471 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Christian M Morgan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457358962 PECOS PAC ID: 1153391636 Enrollment ID: I20091106000349 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Michael H Beus |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982926390 PECOS PAC ID: 3072648666 Enrollment ID: I20100322000497 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Mark E Wilson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1881608800 PECOS PAC ID: 4789589920 Enrollment ID: I20100702000267 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Michael R Pieper |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174717128 PECOS PAC ID: 2163568247 Enrollment ID: I20100726000786 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Niki M Milleson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1225155997 PECOS PAC ID: 9537214309 Enrollment ID: I20101004001427 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Kitchener P Head |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538195417 PECOS PAC ID: 7214121706 Enrollment ID: I20101028000879 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Allen D Carter |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1073549952 PECOS PAC ID: 3678757366 Enrollment ID: I20110404000729 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Noel B Stibor |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750327979 PECOS PAC ID: 4082898788 Enrollment ID: I20110404000808 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | William H Kennington |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1174818769 PECOS PAC ID: 3476723503 Enrollment ID: I20110829000687 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Dirk E Bigler |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1457304776 PECOS PAC ID: 7618900374 Enrollment ID: I20111209000397 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brent V Bowles |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1245564434 PECOS PAC ID: 5698810935 Enrollment ID: I20121119000218 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Bradley Dee Mangum |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235465147 PECOS PAC ID: 5092845883 Enrollment ID: I20130214000449 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Michael Hunt |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1760786362 PECOS PAC ID: 2365626850 Enrollment ID: I20130614000048 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Samuel W Linford |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1306091046 PECOS PAC ID: 6608025986 Enrollment ID: I20130919000722 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Aaron R Brown |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1154653178 PECOS PAC ID: 3476682402 Enrollment ID: I20131211002072 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jessica Draney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295162105 PECOS PAC ID: 3678797917 Enrollment ID: I20140606001414 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Chad A Bagley |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1346483666 PECOS PAC ID: 7214086925 Enrollment ID: I20140813000896 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jonah J Green |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1013079524 PECOS PAC ID: 8123029378 Enrollment ID: I20140814002261 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Korry Wheeler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013307768 PECOS PAC ID: 3577881317 Enrollment ID: I20150408000006 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Sean Elliott Knighton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043549157 PECOS PAC ID: 6507997293 Enrollment ID: I20150529002515 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brent Donald Wilson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1831121938 PECOS PAC ID: 3971516303 Enrollment ID: I20150706002398 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Robert D Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619228186 PECOS PAC ID: 7416108329 Enrollment ID: I20150921001948 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brian S Mcclure |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1184918781 PECOS PAC ID: 9739488982 Enrollment ID: I20160629003185 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Andrew J Hoene |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1821230384 PECOS PAC ID: 9739347113 Enrollment ID: I20160721001655 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Kevin L Stucki |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1306975701 PECOS PAC ID: 0345332698 Enrollment ID: I20160909001282 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Hans Ayres |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528511375 PECOS PAC ID: 7517254873 Enrollment ID: I20160929002669 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | John F Murray |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1568403830 PECOS PAC ID: 4082512819 Enrollment ID: I20161121001020 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brad David Oliverson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1366705444 PECOS PAC ID: 1052622404 Enrollment ID: I20170123002855 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brett Scott Talbot |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1356630420 PECOS PAC ID: 9335434091 Enrollment ID: I20170606000883 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Bruce L Forsyth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992799605 PECOS PAC ID: 0042285215 Enrollment ID: I20170713000350 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Erich M Hunsaker |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1356643589 PECOS PAC ID: 2860630829 Enrollment ID: I20170724003886 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Clayton J Brown |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033557657 PECOS PAC ID: 2062711211 Enrollment ID: I20170728003205 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Clint Allred |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1609190172 PECOS PAC ID: 6103067467 Enrollment ID: I20171205003462 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Richard Brad Washburn |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1497998900 PECOS PAC ID: 9032435003 Enrollment ID: I20171221001358 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Erik C Mcclure |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1033471602 PECOS PAC ID: 0345497418 Enrollment ID: I20180419001197 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Robin Trost |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023494093 PECOS PAC ID: 2769791201 Enrollment ID: I20180614002802 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Mark Wayne Larsen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689166266 PECOS PAC ID: 8325395296 Enrollment ID: I20180724000964 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jack Hojjat Morshedzadeh |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1447381447 PECOS PAC ID: 1850446220 Enrollment ID: I20180724004168 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Zackary M Hale |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1861599912 PECOS PAC ID: 8426010182 Enrollment ID: I20181023000458 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jason E. Sharp |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366470510 PECOS PAC ID: 7012920440 Enrollment ID: I20181213001448 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Todd M Haderlie |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326059155 PECOS PAC ID: 0446273098 Enrollment ID: I20190403000504 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Drew Ernest Polson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700084829 PECOS PAC ID: 4587856257 Enrollment ID: I20190409001264 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Ezekial Cruz Mendenhall |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245611987 PECOS PAC ID: 8729329073 Enrollment ID: I20190415000509 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Gina Lee Snow |
|---|---|
| Provider Type | Practitioner - Other (non-physician) |
| Provider Identifiers | NPI Number: 1275035206 PECOS PAC ID: 2668715632 Enrollment ID: I20190514001772 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Landon B Bluemel |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1023402955 PECOS PAC ID: 4587945076 Enrollment ID: I20190715001699 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Gina Lee Snow |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1275035206 PECOS PAC ID: 2668715632 Enrollment ID: I20190806000946 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Mark J Cowan |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1740626183 PECOS PAC ID: 9537428792 Enrollment ID: I20190819002628 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Daphne A Kontos |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1437579240 PECOS PAC ID: 4789922410 Enrollment ID: I20191029002776 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Darin W Allred |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1316074313 PECOS PAC ID: 7719913524 Enrollment ID: I20200115002255 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Hayden Datwyler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1023636081 PECOS PAC ID: 9638596083 Enrollment ID: I20200831000650 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Laurie L Hanson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770880965 PECOS PAC ID: 8527485739 Enrollment ID: I20200902002901 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jacqueline E Clark |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215452958 PECOS PAC ID: 8628497369 Enrollment ID: I20200930001976 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Joel Gardner |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1942329883 PECOS PAC ID: 6507902731 Enrollment ID: I20201119001473 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Spencer Burk |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1598031742 PECOS PAC ID: 7012250426 Enrollment ID: I20201119003166 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Vincent Call |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1699111245 PECOS PAC ID: 3274888730 Enrollment ID: I20210104002021 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Ryker M Kiel |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1528450327 PECOS PAC ID: 9830434133 Enrollment ID: I20210506001684 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Sara C Burnside |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023468634 PECOS PAC ID: 5597165779 Enrollment ID: I20210609001502 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Kristle J Westover |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780097709 PECOS PAC ID: 7517367774 Enrollment ID: I20210610000964 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Tracy D Osborne |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306187158 PECOS PAC ID: 6709013790 Enrollment ID: I20210628003040 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | David Draney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144471061 PECOS PAC ID: 1153482013 Enrollment ID: I20211025001521 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Elizabeth K Miller |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1679803654 PECOS PAC ID: 5597155846 Enrollment ID: I20211201001210 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Wade K Jensen |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1730139890 PECOS PAC ID: 4486752706 Enrollment ID: I20220222002696 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Anees Daud |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134547623 PECOS PAC ID: 5294043956 Enrollment ID: I20220405001596 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | David Gonzalez |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1043208218 PECOS PAC ID: 0648276204 Enrollment ID: I20220420002425 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Donna Givens |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811063407 PECOS PAC ID: 9537257092 Enrollment ID: I20220426002405 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Dustin Tew |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568821163 PECOS PAC ID: 7315225752 Enrollment ID: I20220513000905 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Donald Howser |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750389425 PECOS PAC ID: 9234212432 Enrollment ID: I20221129002344 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Tara Liddiard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851999411 PECOS PAC ID: 7214348903 Enrollment ID: I20221212001444 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Brian Affleck |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1386633824 PECOS PAC ID: 4183715436 Enrollment ID: I20221215002555 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Katarzyna Lameka |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1164711487 PECOS PAC ID: 9234394073 Enrollment ID: I20221230001038 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Kyle Paul Arslanian |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1144752882 PECOS PAC ID: 5597147819 Enrollment ID: I20230301002230 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Stephen G Chang |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568451284 PECOS PAC ID: 9234110008 Enrollment ID: I20230330000347 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Mark Slepian |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558350314 PECOS PAC ID: 3779488960 Enrollment ID: I20230921000696 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | William Theodorou |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1063686624 PECOS PAC ID: 9436399722 Enrollment ID: I20231013001041 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Craig Edward Hancock |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982693693 PECOS PAC ID: 7517871940 Enrollment ID: I20231013001119 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Mark E. Dearing |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1386669372 PECOS PAC ID: 9436165321 Enrollment ID: I20231023003006 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Eric Schackmuth |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1205817186 PECOS PAC ID: 7416853718 Enrollment ID: I20231024002434 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Randall Haschke |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1114018256 PECOS PAC ID: 2668661307 Enrollment ID: I20231106003392 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Julia Peters |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1154613255 PECOS PAC ID: 8426360710 Enrollment ID: I20231120000740 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Joshua Christiansen |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1184067373 PECOS PAC ID: 2961623038 Enrollment ID: I20240110003286 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
| Provider Name | Jared Tyler |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1609198142 PECOS PAC ID: 8022234186 Enrollment ID: I20240123003595 |
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
News Archive
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
As President Barack Obama and congressional leaders continue discussions to avert the so-called fiscal cliff -; the mix of tax increases and spending cuts set to take effect automatically in January -; we hear a troubling but familiar refrain in Washington: To fix our deficit, we must cut Medicare benefits.
The shooting of an unarmed teenager in Ferguson, MO, has ignited a global discussion about implicit racial bias. One group of people you might think would be immune from this hidden bias is clinical therapists, people trained to understand the human mind. But a new field study finds that the social identities of patients and their therapists affect the accuracy of the diagnosis: Therapists were twice as likely to misdiagnose mental illness when their patients were members of a disadvantaged, compared to an advantaged, group.
› Verified 2 days ago
Sterling Physician Group Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 47 Doc Perkes Rd, Afton, WY 83110 Phone: 307-885-3637 Fax: 307-885-3638 | |
High Country Behavioral Health Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 389 Adams St., Afton, WY 83110 Phone: 307-885-9883 Fax: 307-885-5206 | |
High Country Behavioral Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 389 Adams Street, Afton, WY 83110 Phone: 307-885-9883 Fax: 307-885-5206 | |
Imed Utah Heart - Afton Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 110 Hospital Ln, Afton, WY 83110 Phone: 801-507-3500 | |
Sterling Provider Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 47 Doc Perkes Rd, Afton, WY 83110 Phone: 307-885-3637 Fax: 307-885-3638 |